$622 Million is the total value of COMMODORE CAPITAL LP's 30 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AKRO | New | AKERO THERAPEUTICS INC | $25,315,000 | – | 743,472 | +100.0% | 4.07% | – |
New | THIRD HARMONIC BIO INC | $19,322,000 | – | 1,018,569 | +100.0% | 3.11% | – | |
SNDX | New | SYNDAX PHARMACEUTICALS INC | $17,737,000 | – | 738,110 | +100.0% | 2.85% | – |
ABOS | New | ACUMEN PHARMACEUTICALS INC | $11,033,000 | – | 1,100,000 | +100.0% | 1.77% | – |
ALLK | New | ALLAKOS INC | $10,058,000 | – | 1,643,500 | +100.0% | 1.62% | – |
ALPN | New | ALPINE IMMUNE SCIENCES INC | $9,540,000 | – | 1,325,000 | +100.0% | 1.53% | – |
ENTA | New | ENANTA PHARMACEUTICALS INC | $5,368,000 | – | 103,494 | +100.0% | 0.86% | – |
ESPR | New | ESPERION THERAPEUTICS INC NE | $3,132,000 | – | 467,468 | +100.0% | 0.50% | – |
LRMR | New | LARIMAR THERAPEUTICS INC | $2,400,000 | – | 750,000 | +100.0% | 0.39% | – |
TERN | New | TERNS PHARMACEUTICALS INC | $1,213,000 | – | 205,870 | +100.0% | 0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
CELCUITY INC | 10 | Q3 2023 | 7.3% |
KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-19 |
SC 13G | 2024-03-21 |
13F-HR/A | 2024-02-14 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.